» Articles » PMID: 22836161

Separation of Advanced from Mild Hepatic Fibrosis by Quantification of the Hepatobiliary Uptake of Gd-EOB-DTPA

Overview
Journal Eur Radiol
Specialty Radiology
Date 2012 Jul 28
PMID 22836161
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To apply dynamic contrast-enhanced (DCE) MRI on patients presenting with elevated liver enzymes without clinical signs of hepatic decompensation in order to quantitatively compare the hepatocyte-specific uptake of Gd-EOB-DTPA with histopathological fibrosis stage.

Methods: A total of 38 patients were prospectively examined using 1.5-T MRI. Data were acquired from regions of interest in the liver and spleen by using time series of single-breath-hold symmetrically sampled two-point Dixon 3D images (non-enhanced, arterial and venous portal phase; 3, 10, 20 and 30 min) following a bolus injection of Gd-EOB-DTPA (0.025 mmol/kg). The signal intensity (SI) values were reconstructed using a phase-sensitive technique and normalised using multiscale adaptive normalising averaging (MANA). Liver-to-spleen contrast ratios (LSC_N) and the contrast uptake rate (K (Hep)) were calculated. Liver biopsy was performed and classified according to the Batts and Ludwig system.

Results: Area under the receiver-operating characteristic curve (AUROC) values of 0.71, 0.80 and 0.78, respectively, were found for K (Hep), LSC_N10 and LSC_N20 with regard to severe versus mild fibrosis. Significant group differences were found for K (Hep) (borderline), LSC_N10 and LSC_N20.

Conclusions: Liver fibrosis stage strongly influences the hepatocyte-specific uptake of Gd-EOB-DTPA. Potentially the normalisation technique and K (Hep) will reduce patient and system bias, yielding a robust approach to non-invasive liver function determination.

Citing Articles

Assessment of hepatic transporter function in rats using dynamic gadoxetate-enhanced MRI: a reproducibility study.

Gunwhy E, Hines C, Green C, Laitinen I, Tadimalla S, Hockings P MAGMA. 2024; 37(4):697-708.

PMID: 39105950 PMC: 11417070. DOI: 10.1007/s10334-024-01192-5.


Assessing regional hepatic function changes after hypertrophy induction by radioembolisation: comparison of gadoxetic acid-enhanced MRI and Tc-mebrofenin hepatobiliary scintigraphy.

Fabritius M, Garlipp B, Ocal O, Puhr-Westerheide D, Amthauer H, Geyer T Eur Radiol Exp. 2024; 8(1):15.

PMID: 38282160 PMC: 10822831. DOI: 10.1186/s41747-023-00409-x.


Mathematical models for biomarker calculation of drug-induced liver injury in humans and experimental models based on gadoxetate enhanced magnetic resonance imaging.

Karlsson M, Simonsson C, Dahlstrom N, Cedersund G, Lundberg P PLoS One. 2023; 18(1):e0279168.

PMID: 36608050 PMC: 9821424. DOI: 10.1371/journal.pone.0279168.


Liver-spleen contrast standardization of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging based on cross-calibration.

Mori H, Akimoto S Quant Imaging Med Surg. 2022; 12(12):5343-5357.

PMID: 36465824 PMC: 9703119. DOI: 10.21037/qims-22-174.


The Efficiency of Fractional Anisotropy, Apparent Diffusion Coefficient, and Contrast Enhancement Index in Liver Fibrosis Staging.

Percem Orhan Soylemez U, Mut D, Alkim C, Alkim H, Yilmaz Ozguven B, Boga S Sisli Etfal Hastan Tıp Bul. 2022; 56(1):113-118.

PMID: 35515969 PMC: 9040295. DOI: 10.14744/SEMB.2021.33396.


References
1.
Piccinino F, Sagnelli E, Pasquale G, Giusti G . Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2(2):165-73. DOI: 10.1016/s0168-8278(86)80075-7. View

2.
Bonekamp S, Kamel I, Solga S, Clark J . Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?. J Hepatol. 2008; 50(1):17-35. DOI: 10.1016/j.jhep.2008.10.016. View

3.
Rydell J, Knutsson H, Pettersson J, Johansson A, Farneback G, Dahlqvist O . Phase sensitive reconstruction for water/fat separation in MR imaging using inverse gradient. Med Image Comput Comput Assist Interv. 2007; 10(Pt 1):210-8. DOI: 10.1007/978-3-540-75757-3_26. View

4.
Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

5.
Ehman R . Science to practice: can MR elastography be used to detect early steatohepatitis in fatty liver disease?. Radiology. 2009; 253(1):1-3. DOI: 10.1148/radiol.2531091040. View